Amrutanjan Health Care Limited has informed the Exchange regarding Outcome of Board Meeting held on May 15, 2025.

Results View source PDF Explain this filing

AMRUTANJAN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-2.2%Reaction day

₹715.00

prior close

₹721.95

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.8%-3.0% vs market

Pharmaceuticals peers, median of 150sector+0.2%-2.4% vs sector

On the reaction day the stock moved 3.0 pts less than Nifty Microcap 250 and 2.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.5

10m

-2.3

15m

-1.9

30m

-1.6

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-2.2+0.8-3.0+0.2-2.4

Next day

-1.2+2.0-3.2+1.1-2.4

-3.1+0.9-4.0+0.2-3.3

+0.3+1.7-1.4+1.0-0.7

+2.2+1.6+0.7+1.2+1.1

+0.0+2.2-2.2+0.7-0.7

+2.0+2.7-0.8+1.2+0.8

15d

-0.1+4.5-4.6+0.8-0.9

-2.5+5.6-8.1+2.2-4.7

-1.0+9.0-10.0+4.1-5.1

-0.6+3.5-4.1-0.9+0.3

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 150Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Amrutanjan Health Care's board approved audited results for Q4 and FY ended March 31, 2025. FY25 revenue from operations rose to Rs. 45,181.63 lakhs from Rs. 42,123.05 lakhs (up about 7.3%), while profit after tax grew to Rs. 5,083.47 lakhs from Rs. 4,497.26 lakhs (up about 13%), with EPS at Rs. 17.58 vs Rs. 15.50. Q4 revenue came in at Rs. 13,541.36 lakhs and Q4 PAT at Rs. 1,517.78 lakhs. The board recommended a final dividend of Rs. 2.60 per share, taking total FY25 dividend to Rs. 3.60 per share (including Rs. 1 interim already paid). Statutory auditor BSR & Co. LLP issued an unmodified opinion.

Likely market impact

Steady mid-single-digit revenue growth and low-teens PAT growth, combined with a consistent dividend, suggest a stable, shareholder-friendly year; however, the Women's Hygiene segment continues to post segment-level losses, which is a watchpoint for future quarters.